Navigation Links
CryoLife To Host Aortic Valve and Root Training Session
Date:9/16/2013

ATLANTA, Sept. 16, 2013 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device Company focused on cardiac and vascular surgery, announced today that it will host an Aortic Valve and Root "Boot Camp" training session on September 18-20, 2013 at CryoLife's training facility at its corporate headquarters in suburban Atlanta. The course directors for the training session will be William F. Northrup III, MD, vice president of physician relations and education at CryoLife, and George L. Hicks Jr., MD, Chief of Cardiac Surgery and Professor of Surgery at the University of Rochester Medical Center in Rochester, New York and immediate past president of the Thoracic Surgery Directors Association.

The Aortic Valve and Root "Boot Camp" training session, which is expected to be attended by 32 residents from official Cardiothoracic Surgery training programs who have been selected by the program directors, will focus on four areas of training:

  • Aortic Root Anatomy, AVR, Annulus Enlargement and Myectomy
  • Aortic Repair and Valve-Sparing
  • Aortic Root Replacement
  • Pulmonary Autograft Replacement (Ross Procedure)
  • The program will include 12 internationally recognized academic faculty members from prestigious American Universities.  A full list of faculty and event details can be found at http://www.cryolife.com/physician-education/aortic-valve-and-root-boot-camp.

    Steven G. Anderson, chairman, president and CEO of CryoLife, said, "Physician education programs such as the Aortic Valve and Root Boot Camp are a key component of our strategy to build strong relationships with our surgeon customers. Each year we educate hundreds of physicians and healthcare professionals through sophisticated programs covering our tissue and medical device products. Programs such as this will allow the next generation of cardiac surgeons to become familiar with our tissue products and learn advanced surgical techniques required for complex cardiac repair from a faculty of leading surgeons from around the country."

    About CryoLife, Inc.Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries throughout the U.S., certain countries in Europa, and Canada.  CryoLife's CryoValve® SG pulmonary heart valve, processed using CryoLife's proprietary SynerGraft® technology, has FDA 510(k) clearance for the replacement of diseased, damaged, malformed, or malfunctioning native or prosthetic pulmonary valves.  CryoLife's CryoPatch® SG pulmonary cardiac patch has FDA 510(k) clearance for the repair or reconstruction of the right ventricular outflow tract (RVOT), which is a surgery commonly performed in children with congenital heart defects, such as Tetralogy of Fallot, Truncus Arteriosus, and Pulmonary Atresia.  CryoPatch SG is distributed in three anatomic configurations: pulmonary hemi-artery, pulmonary trunk, and pulmonary branch.  CryoLife's BioGlue® Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels.  BioGlue is also CE marked in the European Community for use in soft tissue repair and was recently approved in Japan for use in the repair of aortic dissections.  Additional marketing approvals for BioGlue have been granted in several other countries throughout the world.  CryoLife, through its subsidiary Cardiogenesis Corporation, specializes in the treatment of coronary artery disease for severe angina using a laser console system and single use, fiber-optic handpieces to perform a surgical procedure known as Transmyocardial Revascularization (TMR).  In addition, CryoLife and its subsidiary Hemosphere, Inc. market the HeRO® Graft, which is a solution for end-stage renal disease in certain hemodialysis patients.  CryoLife distributes PerClot®, an absorbable powder hemostat, in the European Community and other select international countries.  CryoLife's BioFoam Surgical Matrix is CE marked in the European Community for use as an adjunct in the sealing of abdominal parenchymal tissues (liver and spleen) when cessation of bleeding by ligature or other conventional methods is ineffective or impractical. 

    For additional information about CryoLife, visit CryoLife's website, www.cryolife.com.

    Contacts: CryoLife 

    The Ruth Group D. Ashley Lee

    Nick Laudico / Zack KubowExecutive Vice President, Chief Financial Officer
    and Chief Operating Officer 

    646-536-7030 / 7020
    nlaudico@theruthgroup.com
    Phone: 770-419-3355

    zkubow@theruthgroup.com
    '/>"/>

    SOURCE CryoLife, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. CryoLife Announces Quarterly Cash Dividend for the Third Quarter 2013
    2. CryoLife kündigt erste Implantation des HeRO Transplantats in Europa an
    3. CryoLife anuncia el primer implante europeo del injerto HeRO
    4. CryoLife annuncia il primo impianto europeo di HeRO Graft
    5. CryoLife Announces First European Implant Of HeRO Graft
    6. CryoLife Reports Record Second Quarter Revenues
    7. CryoLife Announces Release Date and Teleconference Call Details for 2013 Second Quarter Financial Results
    8. CryoLife Enhances International Presence with Appointment of Andres Sarmiento as Latin America Sales Manager
    9. CryoLife 2013 First Quarter Revenues Grew 10 Percent to a Record $35.5 Million
    10. CryoLife Announces Release Date and Teleconference Call Details for 2013 First Quarter Financial Results
    11. CryoLife Receives FDA Clearance For Next Generation HeRO Device
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/18/2017)... Jan. 18, 2017 The Philadelphia Pediatric Medical Device ... medical devices for children. The Consortium chose those ... grants of $50,000 each. The devices under development ... signals, a hand-operated rapid blood delivery system for emergency situations ... ...
    (Date:1/18/2017)... , Jan. 18, 2017   Spotlight Innovation ... Caretta Therapeutics plans, in the second quarter of ... topical roll-on intended to provide relief from chronic ... steroidal analgesics. It was developed under a licensing ... commercialize products derived from snake venom. Additionally, Caretta ...
    (Date:1/18/2017)... Md. , Jan. 18, 2017  Kratom ... the coffee family, are often used to prepare ... consumed by several million Americans annually to increase ... a natural remedy for minor aches and pains. ... effects is intended to assist FDA and DEA ...
    Breaking Medicine Technology:
    (Date:1/19/2017)... Antonio, TX (PRWEB) , ... January 19, 2017 , ... ... has for the fifth consecutive year donated money to the Triumph Over Kid Cancer ... A. Ragan was one of those children. James saw firsthand the effect of the ...
    (Date:1/19/2017)... ... January 18, 2017 , ... The CHP suggests that California drivers can avoid ... slowing down and increasing the space between themselves and other vehicles, according to a ... attorney Raymond R. Hassanlou notes that, rain or shine, drivers should always incorporate safe ...
    (Date:1/19/2017)... ... , ... The 21st Century Cures Act’s Impact on Medical Devices:, What You ... 1:30 p.m. – 3:00 p.m. ET, http://www.fdanews.com/21stcenturycures          , What do ... this year? , The passage of the act means devicemakers will be scrambling to ...
    (Date:1/19/2017)... ... 19, 2017 , ... Infinity® Massage Chairs announced today that Dan Grover has ... marketing strategies. Grover comes with a total of 15 years experience in consumer goods ... Executive Vice President of Direct Sales at Traeger® Wood Pellet Grills. , Grover ...
    (Date:1/19/2017)... ... January 19, 2017 , ... ... age-related lines and wrinkles. Few people know that popular cosmetic fillers ... Richard Buckley, who is medical director of the MilfordMD Cosmetic Dermatology Surgery & ...
    Breaking Medicine News(10 mins):